From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study
Treatment response
N (%)
Complete response (CR)
2 (1.9)
Very good partial response (VGPR)
40 (37.4)
Partial response (PR)
46 (43)
Mixed response (MR)
19 (17.8)
No response (NR)
–
Progressive disease (PD)